Beyond The Numbers: 4 Analysts Discuss SI-BONE Stock
Portfolio Pulse from Benzinga Insights
SI-BONE (NASDAQ:SIBN) has been analyzed by 4 analysts, showing a mix of bullish to bearish sentiments. Recent ratings include 3 bullish, 1 somewhat bullish, and a decrease in the average 12-month price target to $25.00 from $25.33. Analysts from Cantor Fitzgerald, Truist Securities, and Needham have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. SI-BONE, a medical device company, has shown notable revenue growth of 28.68% as of September 30, 2023, but struggles with profitability and asset utilization.
February 27, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
SI-BONE has received mixed analyst ratings with a slight decrease in the average price target. The company shows strong revenue growth but faces profitability and asset utilization challenges.
The mixed analyst ratings and slight decrease in the price target suggest a neutral short-term impact on SIBN's stock price. However, the company's significant revenue growth could be a positive signal to investors, potentially offsetting concerns about profitability and asset utilization.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100